United States · Funded startup

Who invested in Korro Bio

One round we have observed, with the 3 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Raised 8 months ago

Funding summaryUpdated 26 Oct 2026

$85Mraised across 1 round since 2026, from 1 source

Latest round
Round, $85MMar 2026
Investors
3
See who backed them

The rounds

  1. Mar 2026

Founders and team

From the SEC filings it signed: 2 on the team.

  • Nessan BerminghamMr. Bermingham is the Executive Chair of the Issuer.i
  • Ommer ChohanMr. Chohan is the Secretary and Treasurer of the Issuer.i

On the board, as filediJean-Francois Formela

Everyone who backed them

Cormorant Asset ManagementPrivate equity1round
Blue OwlAsset manager1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Korro Bio as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

Atlas VentureVC firmPer its own site

Quick answers about Korro Bio

Who invested in Korro Bio?

Korro Bio's investors include New Enterprise Associates, Cormorant Asset Management and Blue Owl.

How much has Korro Bio raised?

Korro Bio has raised $85M across 1 round since 2026.

When did Korro Bio last raise?

Korro Bio's most recent round was an Undisclosed round of $85M in Mar 2026.

What was Korro Bio's biggest round?

Its most recent round, $85M in Mar 2026, is also its largest on record.

Who backed Korro Bio first?

Korro Bio's first round on record, in Mar 2026, was backed by New Enterprise Associates, Cormorant Asset Management and Blue Owl.

What stage is Korro Bio at?

Korro Bio's latest named round is an Undisclosed round, in Mar 2026.

Where is Korro Bio based?

Korro Bio is based in the United States.

Companies like Korro Bio

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.